Pharmicell’s stem cell therapy from clinical trials (phase 2) is positively effective in treating liver cirrhosis
Pharmicell (co-headed by Kim, Hyeon-Soo and Kim, Seong-Rae, 005690) successfully ended “The 6th Pharmicell Regular Symposium” held on 19th with 250 participants.
The symposium has become more meaningful in that experts from industry, academia, and research gather together under the theme of ‘Current Status of the next generation Stem Cell and Bio-Chemical new drugs development’.
Notably, the positive results of the clinical trials (phase 2) on Pharmicell’s stem cell therapy for liver cirrhosis named ‘Cellgram-liver’ were drawing a great attention in the session of ‘Current Status of Stem Cell Therapeutics Clinical Trials’.
The trials selected as part of Health and Welfare Ministry’s cutting-edge technology development project in 2004 have been carried out on patients suffering from liver cirrhosis at leading hospitals including Yonsei University Wonju Sevrance Christian Hospital and The Catholic University of Korea Seoul St. Marys’ Hospital.
Kim Hyun Soo cited the clinical trial results presented by Prof. Bae Si Hyun from College of Medicine, the Catholic University of Korea at the Korean association for the study of the liver at his presentation. “Histological/haematological examination shows that patients diagnosed with liver cirrhosis got much better after being administered with Pharmicell’s stem cell cures,” Kim said. “I am happy to give this good news to the patients with no alternative options other than a liver transplant.”
Previously, Pharmicell’s research results of treatment effects from the clinical trials were published in the journal of ‘Liver International’, suggesting the possibility of fundamental treatment for patients with liver cirrhosis and its clinical cases were introduced by various media.
“Based on the positive results of phase 2 clinical trials, we are now targeting Phase 3 clinical research to be conducted in the second half of this year and the results will be utilized as useful base data,” said Pharmicell.